Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 15, 2026

E-Learning Research Report 2026-2031: Extensive Product Portfolios, Robust LMS Platforms, and Institutional Partnerships Consolidate Market Leadership

View original at globenewswire.com
E-Learning Research Report 2026-2031: Extensive Product Portfolios, Robust LMS Platforms, and Institutional Partnerships Consolidate Market Leadership Dublin, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global e-learning market is moderately concentrated and highly competitive

    80% confidence

  • The E-Learning Market was valued at USD 325 Billion in 2025, and is projected to reach USD 665.06 Billion by 2031, rising at a CAGR of 12.68%

    80% confidence

  • China is growing at a CAGR of 16.15% during the forecast period

    80% confidence

  • APAC is the second largest share and fastest growing market of the global e-learning market

    80% confidence

  • North America is the largest e-learning market in 2025, with the US accounting for over 80% of the region

    80% confidence

  • The market faces challenges from proliferation of low-cost, open-access, and unregulated content providers, particularly in developing regions

    80% confidence

  • Kahoot! has 8 million teachers and 1.6 billion users globally in 2024

    80% confidence

  • EU GDP was 1.0% higher in real terms in 2024 than in 2023

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
E-Learning Research Report 2026-2031: Extensive Product Portfolios, Robust LMS Platforms, and Institutional Partnerships Consolidate Market Leadership — Source | Via News | ViaNews EU